SCHEMBL3136448

SCHEMBL3136448

Cc1cc(OCc2ccc(C(=O)O)cc2)c(N(Cc2ccccn2)S(=O)(=O)c2ccccn2)cc1C

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RXRA P19793 6/20 0.46
RXRB P28702 5/20 0.46
RXRG P48443 4/20 0.46
HPGD P15428 2/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TRPM8 Q7Z2W7 2/20 0.42
OXTR P30559 1/20 0.42
TAS2R14 Q9NYV8 1/20 0.39
CXCR3 P49682 1/20 0.38
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
KMT2A Q03164 1/20 0.38
KEAP1 Q14145 1/20 0.38
NFE2L2 Q16236 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL215215 0.87 RXRA (0.46) RXRARXRBRXRGHPGDKDM4E
SCHEMBL3148806 0.87 ALDH1A1 (0.46) RXRARXRBRXRGHPGDKDM4E
SCHEMBL1644361 0.86 RXRA (0.44) RXRARXRBRXRGHPGDKDM4E
SCHEMBL12361934 0.86 RXRA (0.44) RXRARXRBRXRGHPGDKDM4E
SCHEMBL1645342 0.86 RXRA (0.44) RXRARXRBRXRGHPGDKDM4E
SCHEMBL3144808 0.86 RXRA (0.41) RXRARXRBRXRGHPGDKDM4E
SCHEMBL1645226 0.84 RXRA (0.43) RXRARXRBRXRGHPGDKDM4E
SCHEMBL1644379 0.84 RXRA (0.43) RXRARXRBRXRGHPGDKDM4E
SCHEMBL3148767 0.80 TRPM8 (0.43) RXRARXRBRXRGHPGDKDM4E
SCHEMBL3140141 0.80 RXRA (0.41) RXRARXRBRXRGHPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181187-B2 Therapeutic agent for urinary excretion disorder ONO PHARMACEUTICAL CO., LTD. (JP) 2015-11-10 US disclosed
EP-2123273-B1 THERAPEUTIC AGENT FOR URINARY EXCRETION DISORDER ONO PHARMACEUTICAL CO (JP) 2013-10-23 EP disclosed
US-20100076038-A1 THERAPEUTIC AGENT FOR URINARY EXCRETION DISORDER ONO PHARMACEUTICAL CO., LTD. (JP) 2010-03-25 US disclosed
EP-2123273-A1 THERAPEUTIC AGENT FOR URINARY EXCRETION DISORDER ONO Pharmaceutical Co., Ltd. (JP) 2009-11-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076038-A1 THERAPEUTIC AGENT FOR URINARY EXCRETION DISORDER PTGER1, TMPRSS15, EPDR1 RXRA 4540/4885RXRB 4498/4885RXRG 4625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.